{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:44:42Z","timestamp":1761965082893},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>The role of adjuvant tyrosine kinase inhibitors (TKIs) in non\u2013small cell lung cancer (NSCLC) is not well defined. Recent randomized controlled trials showed a disease-free survival (DFS) benefit in patients harboring an epidermal growth factor receptor (EGFR) mutation. Yet, older trials on patients with any EGFR status did not demonstrate the same benefit. We aimed to assess the efficacy and safety of adjuvant TKIs in NSCLC patients. The electronic databases Medline (PubMed) and EMBASE were searched for relevant randomized controlled trials. Random effect models were used. The primary outcome was DFS measured as hazard ratio (HR). The secondary outcomes were overall survival (OS) measured as HR, 2-year DFS and toxicity expressed as risk ratio and odds ratio (OR), respectively. Subgroup analyses assessed DFS by trial design. Six trials incorporating 1860 patients were included. In patients harboring an EGFR mutation, adjuvant TKIs decreased the risk of disease recurrence by 48% (HR: 0.52, 95% confidence interval [CI]: 0.35-0.78), improved 2-year DFS (HR: 0.53, 95% CI: 0.43-0.66) but did not improve OS (HR: 0.64, 95% CI: 0.22-1.89). The risk of developing \u2265grade 3 skin toxicity (OR: 6.07, 95% CI: 4.34-8.51) and diarrhea (OR: 4.05; 95% CI: 2.44-6.74) was increased. In subgroup analyses, the DFS benefit was more pronounced in trials using TKIs over chemotherapy compared with trials using TKIs postchemotherapy. In conclusion, adjuvant TKIs decrease the risk of recurrence in NSCLC patients harboring an EGFR mutation but do not improve OS. Longer follow-up is needed for a definitive assessment of OS and to define the role of adjuvant TKI for NSCLC in the clinical practice.<\/jats:p>","DOI":"10.1097\/coc.0000000000000533","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T20:21:53Z","timestamp":1553631713000},"page":"440-445","source":"Crossref","is-referenced-by-count":15,"title":["Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non\u2013Small Cell Lung Cancer (NSCLC)"],"prefix":"10.1097","volume":"42","author":[{"given":"Jacques","family":"Raphael","sequence":"first","affiliation":[{"name":"London Regional Cancer Program, Department of Oncology, Division of Medical Oncology"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Vincent","sequence":"additional","affiliation":[{"name":"London Regional Cancer Program, Department of Oncology, Division of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Boldt","sequence":"additional","affiliation":[{"name":"London Regional Cancer Program, Department of Oncology, Division of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakesh S.","family":"Shah","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto"},{"name":"Department of Pediatrics, Mount Sinai Hospital, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"London Regional Cancer Program, Department of Oncology, Division of Radiation Oncology, Western University, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Blanchette","sequence":"additional","affiliation":[{"name":"London Regional Cancer Program, Department of Oncology, Division of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data","volume":"375","author":"Arriagada","year":"2010","journal-title":"Lancet"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resectedstage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"R21-20230903","article-title":"A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V, eds. Cochrane Methods","volume":"10","author":"Higgins","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"e0140794","DOI":"10.1371\/journal.pone.0140794","article-title":"Randomized adjuvant chemotherapy of EGFR-mutated non-small cell lung cancer patients with or without icotinib consolidation therapy","volume":"10","author":"Feng","year":"2015","journal-title":"PLoS One"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1245\/s10434-014-3586-9","article-title":"Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study","volume":"21","author":"Li","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.chest.2015.12.017","article-title":"Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis","volume":"149","author":"Huang","year":"2016","journal-title":"Chest"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.21037\/jtd.2017.12.58","article-title":"Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis","volume":"9","author":"Yuan","year":"2017","journal-title":"J Thorac Dis"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201905000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:11:43Z","timestamp":1693710703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201905000-00005"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000533","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}